Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Multiple sclerosis. An update with practical guidelines for ophthalmologists].

T Ziemssen1, H Wilhelm, F Ziemssen

  • 1MS-Zentrum Dresden, Neurologische Universitätsklinik Carl-Gustav Carus, TU Dresden. Focke.Ziemssen@med.uni-tuebingen.de

Der Ophthalmologe : Zeitschrift Der Deutschen Ophthalmologischen Gesellschaft
|July 5, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient profiling in relapsing multiple sclerosis: insights from a real-world observational study into the unmet medical needs of patients on disease-modifying therapy.

Journal of neurology·2026
Same author

Hepatic chemosaturation with melphalan in patients with primary or secondary liver tumors with or without extrahepatic tumor manifestation.

ESMO gastrointestinal oncology·2026
Same author

Brolucizumab and Platelet Activation and Reactivity.

Current eye research·2025
Same author

[Prospective noninterventional BLUE SKY study evaluating the efficacy of brolucizumab in treatment-naïve and previously treated patients with neovascular AMD].

Die Ophthalmologie·2022
Same author

Human Platelets Take up Anti-VEGF Agents.

Journal of ophthalmology·2021
Same author

Patient- versus physician-reported relapses in multiple sclerosis: insights from a large observational study.

European journal of neurology·2020
Same journal

["DOG 2020 online" - for the first time in the von Graefe year].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2024
Same journal

[Are organ and co-cultures an alternative to animal models in ophthalmology?]

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2022
Same journal

[Pediatric corneal opacities : Even small improvements provide lifelong help].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2022
Same journal

[Myxoma of the conjunctiva].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2022
Same journal

[Secondary open-angle glaucoma: uveitic secondary glaucoma, steroid-induced glaucoma, posttraumatic and postoperative glaucoma, tumor-related glaucoma and glaucoma due to elevated episcleral venous pressure].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2022
Same journal

[Artificial intelligence in the management of anti-VEGF treatment: the Vienna fluid monitor in clinical practice].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2022
See all related articles

Multiple sclerosis (MS), a common inflammatory central nervous system disease, often presents with optic neuritis. Early diagnosis and immunomodulatory treatment are crucial to reduce relapses and slow disability progression in MS patients.

Area of Science:

  • Neurology
  • Immunology
  • Ophthalmology

Context:

  • Multiple sclerosis (MS) is the most common chronic inflammatory disease affecting the central nervous system.
  • Young adults are frequently diagnosed with MS, presenting diverse symptoms due to inflammatory lesions in various locations.
  • Optic neuritis is a common initial symptom, making ophthalmologists often the first point of contact for future MS patients.

Purpose:

  • To provide an interdisciplinary overview of current knowledge on MS pathogenesis, diagnosis, and treatment.
  • To establish guidelines for clinical practice regarding risk assessment and patient management.
  • To emphasize the importance of early diagnosis and intervention in MS.

Summary:

  • MS involves irreversible axonal loss from the disease's onset, necessitating prompt diagnosis and treatment.

Related Experiment Videos

  • Early immunomodulatory therapy aims to minimize disease relapses and decelerate the progression of clinical disability.
  • Guidelines are presented for assessing individual patient risk and tailoring treatment based on current scientific understanding.

    • Impact:

    • Facilitates early detection and intervention for MS patients, potentially improving long-term outcomes.
    • Supports clinicians in managing MS by integrating pathogenic, diagnostic, and therapeutic advancements.
    • Highlights the critical role of ophthalmologists in the early identification of MS.